Cardiotoxicity prevention trials in the era of contemporary cancer therapies: a systematic review
Cardiooncology
.
2026 Apr 11.
doi: 10.1186/s40959-026-00464-4.
Online ahead of print.
Authors
Malak Munir
#
1
,
Ahmed Sayed
#
2
,
Sanam Ghazi
3
,
Eric H Yang
4
,
Avirup Guha
5
,
Narendranath Epperla
6
,
Daniel Addison
7
8
9
Affiliations
1
Karsh Division of Gastroenterology and Hepatology, Cedars-Sinai Medical Center, Los Angeles, CA, USA.
2
Houston Methodist DeBakey Heart & Vascular Center, Houston, TX, USA.
3
Cardio-Oncology Program, University of Texas Southwestern Medical Center, Texas, USA.
4
Division of Cardiology, Department of Medicine, UCLA Cardio-Oncology Program, University of California at Los Angeles, Los Angeles, CA, USA.
5
Cardio-Oncology Program, Augusta University Medical Center, Augusta, GA, USA.
6
Division of Hematology and Hematologic Malignancies, Huntsman Cancer Institute, University of Utah, Salt Lake City, UT, USA.
7
Cardio-Oncology Program, University of Texas Southwestern Medical Center, Texas, USA. daniel.addison@utsouthwestern.edu.
8
Simmons Comprehensive Cancer Center, University of Texas Southwestern Medical Center, Texas, USA. daniel.addison@utsouthwestern.edu.
9
Division of Cardiovascular Medicine, 6000 Harry Hines Blvd, Suite NB11.200, Dallas, TX, 75235, USA. daniel.addison@utsouthwestern.edu.
#
Contributed equally.
PMID:
41965742
DOI:
10.1186/s40959-026-00464-4
No abstract available
Keywords:
Cancer therapies; Cardio-oncology; Cardiotoxicity prevention trials.
Grants and funding
P50-CA140158/NH/NIH HHS/United States
847740/American Heart Association
American Heart Association-Robert Wood Johnson Foundation grant/American Heart Association